These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 20414023)

  • 21. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31.
    Tan-Chiu E; Yothers G; Romond E; Geyer CE; Ewer M; Keefe D; Shannon RP; Swain SM; Brown A; Fehrenbacher L; Vogel VG; Seay TE; Rastogi P; Mamounas EP; Wolmark N; Bryant J
    J Clin Oncol; 2005 Nov; 23(31):7811-9. PubMed ID: 16258083
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cardiac toxicity of trastuzumab in metastatic breast cancer patients previously treated with high-dose chemotherapy: a retrospective study.
    Bengala C; Zamagni C; Pedrazzoli P; Matteucci P; Ballestrero A; Da Prada G; Martino M; Rosti G; Danova M; Bregni M; Jovic G; Guarneri V; Maur M; Conte PF;
    Br J Cancer; 2006 Apr; 94(7):1016-20. PubMed ID: 16570045
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Risk of cardiac dysfunction with trastuzumab in breast cancer patients: a meta-analysis.
    Chen T; Xu T; Li Y; Liang C; Chen J; Lu Y; Wu Z; Wu S
    Cancer Treat Rev; 2011 Jun; 37(4):312-20. PubMed ID: 20952131
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Protocol for administration of trastuzumab based on cardiac function].
    Okada Y; Kaneko K; Kanbayashi C; Sato N
    Gan To Kagaku Ryoho; 2012 Jun; 39(6):915-9. PubMed ID: 22705685
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Multicenter phase II study of trastuzumab in combination with epirubicin and docetaxel as first-line treatment for HER2-overexpressing metastatic breast cancer.
    Venturini M; Bighin C; Monfardini S; Cappuzzo F; Olmeo N; Durando A; Puglisi F; Nicoletto O; Lambiase A; Del Mastro L
    Breast Cancer Res Treat; 2006 Jan; 95(1):45-53. PubMed ID: 16267615
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Trastuzumab-related cardiac events in the treatment of early breast cancer.
    Fried G; Regev T; Moskovitz M
    Breast Cancer Res Treat; 2013 Nov; 142(1):1-7. PubMed ID: 24154507
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Reversibility of Left Ventricle Longitudinal Strain Alterations Induced by Adjuvant Therapy in Early Breast Cancer Patients.
    Mele D; Malagutti P; Indelli M; Ferrari L; Casadei F; Da Ros L; Pollina A; Fiorencis A; Frassoldati A; Ferrari R
    Ultrasound Med Biol; 2016 Jan; 42(1):125-32. PubMed ID: 26603736
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Management of trastuzumab-related cardiac dysfunction.
    Carver JR
    Prog Cardiovasc Dis; 2010; 53(2):130-9. PubMed ID: 20728700
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lack of uniformity in cardiac assessment during trastuzumab therapy.
    Subar M; Lin W; Chen W; Pittman DG
    Breast J; 2011; 17(4):383-90. PubMed ID: 21615821
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Acute cardiotoxicity with concurrent trastuzumab and radiotherapy including internal mammary chain nodes: a retrospective single-institution study.
    Shaffer R; Tyldesley S; Rolles M; Chia S; Mohamed I
    Radiother Oncol; 2009 Jan; 90(1):122-6. PubMed ID: 18976826
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Trastuzumab-associated cardiotoxicity.
    Keefe DL
    Cancer; 2002 Oct; 95(7):1592-600. PubMed ID: 12237930
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Adjuvant trastuzumab in routine clinical practice and the impact of cardiac monitoring guidelines on treatment delivery.
    Murray LJ; Ramakrishnan S; O'Toole L; Manifold IH; Purohit OP; Coleman RE
    Breast; 2010 Oct; 19(5):339-44. PubMed ID: 20226661
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pegylated liposomal doxorubicin and trastuzumab as 1st and 2nd line therapy in her2/neu positive metastatic breast cancer: a multicenter phase II trial.
    Stickeler E; Klar M; Watermann D; Geibel A; Földi M; Hasenburg A; Gitsch G
    Breast Cancer Res Treat; 2009 Oct; 117(3):591-8. PubMed ID: 19156515
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm.
    Burstein HJ; Harris LN; Marcom PK; Lambert-Falls R; Havlin K; Overmoyer B; Friedlander RJ; Gargiulo J; Strenger R; Vogel CL; Ryan PD; Ellis MJ; Nunes RA; Bunnell CA; Campos SM; Hallor M; Gelman R; Winer EP
    J Clin Oncol; 2003 Aug; 21(15):2889-95. PubMed ID: 12885806
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Trastuzumab-induced cardiotoxicity in early breast cancer patients: a retrospective study of possible risk and protective factors.
    Farolfi A; Melegari E; Aquilina M; Scarpi E; Ibrahim T; Maltoni R; Sarti S; Cecconetto L; Pietri E; Ferrario C; Fedeli A; Faedi M; Nanni O; Frassineti GL; Amadori D; Rocca A
    Heart; 2013 May; 99(9):634-9. PubMed ID: 23349345
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cardiac safety of trastuzumab in combination with epirubicin and cyclophosphamide in women with metastatic breast cancer: results of a phase I trial.
    Untch M; Eidtmann H; du Bois A; Meerpohl HG; Thomssen Ch; Ebert A; Harbeck N; Jackisch C; Heilman V; Emons G; Wallwiener D; Wiese W; Blohmer JU; Höffken K; Kuhn W; Reichardt P; Muscholl M; Pauschinger M; Langer B; Lück HJ
    Eur J Cancer; 2004 May; 40(7):988-97. PubMed ID: 15093573
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Two cases with have a complication in cardiac function during chemotherapy with trastuzumab].
    Ishizaki A; Katayama K; Negishi T; Kamisaka K
    Gan To Kagaku Ryoho; 2007 Apr; 34(4):639-41. PubMed ID: 17431357
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment.
    Ewer MS; Vooletich MT; Durand JB; Woods ML; Davis JR; Valero V; Lenihan DJ
    J Clin Oncol; 2005 Nov; 23(31):7820-6. PubMed ID: 16258084
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Trastuzumab-associated cardiac events at 8 years of median follow-up in the Herceptin Adjuvant trial (BIG 1-01).
    de Azambuja E; Procter MJ; van Veldhuisen DJ; Agbor-Tarh D; Metzger-Filho O; Steinseifer J; Untch M; Smith IE; Gianni L; Baselga J; Jackisch C; Cameron DA; Bell R; Leyland-Jones B; Dowsett M; Gelber RD; Piccart-Gebhart MJ; Suter TM
    J Clin Oncol; 2014 Jul; 32(20):2159-65. PubMed ID: 24912899
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [A case of breast cancer with repeated cardiac dysfunction due to trastuzumab].
    Tokuda A; Abe H; Kawai Y; Umeda T; Tomida K; Mori T; Cho H; Kubota Y; Tani T
    Gan To Kagaku Ryoho; 2014 Mar; 41(3):365-7. PubMed ID: 24743285
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.